Taysha Gene Therapies (NASDAQ: TSHA) is a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease.
Location: United States
Total raised: $125M
Investors 4
| Date | Name | Website |
| - | PBM Capita... | pbmcap.com |
| - | Octagon Ca... | octagoninv... |
| - | Trinity Ca... | trinitycap... |
| 10.07.2021 | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.08.2020 | Series B | $95M | - |
| 29.04.2020 | Seed | $30M | - |
Mentions in press and media 19
| Date | Title | Description |
| 13.06.2025 | Signify Bio: $15 Million Raised For Creating Personalized Medicines | Signify Bio, which is a pioneering biotechnology company harnessing the human body for the production of in situ protein therapeutics, announced an oversubscribed $15 million initial financing. The funding round was led by Actium Group with... |
| 01.04.2025 | S&P, Nasdaq post big quarterly percentage drops on Trump tariff turmoil | S&P, Nasdaq post big quarterly percentage drops on Trump tariff turmoil By David FrenchApril 1, 202512:09 AM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link SummaryCompanies S&P, Nasdaq pos... |
| 05.08.2024 | Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12 | DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central... |
| 14.08.2023 | Taysha Gene Therapies Announces $150 Million Private Placement Financing | - |
| 26.10.2022 | Vaxcyte's data lead to $600M haul, while Taysha looks to raise cash after Astellas deal | It’s only been a few days since Vaxcyte gave the biotech world a peek at data for its 24-valent pneumococcal vaccine, but the company is looking more and more confident as it opens up a nine-figure public offering. On Wedne... |
| 27.01.2022 | Taysha Gene Therapies : Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of ß-Hexosaminidase A Enzyme Act... | Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of ß-Hexosaminidase A Enzyme Activity in Patients with GM2 Gangliosidosis ... |
| 10.11.2021 | Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K | Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update Anticipate clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in GAN in December 2021 Exp... |
| 05.10.2021 | Taysha Gene Therapies : Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Nex... | Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batt... |
| 16.08.2021 | Taysha Gene Therapies, Inc. Secures Up to $100 Million Non-Dilutive Term Loan Financing | Taysha Gene Therapies, Inc. announced that it has entered into a loan and security agreement with Silicon Valley Bank (SVB) that provides Taysha with up to $100 million of borrowing capacity. This non-dilutive financing provides Taysha with... |
| 16.08.2021 | Taysha Gene Therapies : Secures up to $100 Million Non-Dilutive Term Loan Financing | Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and lar... |
Show more